<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100130003226N19</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-28</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation the effect of Malva sylvestris L extract ointment on pain intensity and incision of during delivery wound healing in primiparous women</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of Malva sylvestris L extract ointment and placebo on pain intensity and episiotomy wound healing in primiparous women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>112</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66636</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: It is available (simple) and goal based. In this way, all patients who are eligible for the study will be screened. The delivery of medicine to the patients in a box containing several cards that are evenly written in the English alphabet "A and B" with the placebo and Malva sylvestris L ointment code (researcher unaware of the content of the ointments) we match and patients randomly choose a card and receive the medicine according to the letters on the card, Blinding description: This study is a kind of triple-blind randomized controlled clinical trial. At the diagnostic stage, the demographic forms and obstetric and delivery questionnaire are not completed and the patient's name is not written. At the stage of giving medicine to the patient, a placebo and Malva-sylvestris-L ointment are marked with the English letter A and B coded by the pharmacist. The researcher is not aware of the contents of the ointments and the patient also randomly selects one of the placeboes or Malva-sylvestris-L ointments the statistic professor is also unaware of the intervention and control groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Episiotomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: Uses 3% Malva sylvestris L ointment for 10 days (daily) at a rate of two centimeters, on episiotomy wound. This ointment is produced at the Faculty of Pharmacy of Shahid Beheshti University of Medical Sciences. Initial assessment of pain intensity and wound healing is done before the intervention, 24 hours after the intervention and then on the fifth and tenth days. Intervention 2: Control group: Control group: Use placebo ointment (quite similar to Malva sylvestris L ointment) for 2 days (daily) at 2 cm, on episiotomy ulcer. This ointment is produced at the Faculty of Pharmacy of Shahid Beheshti University of Medical Sciences. Initial assessment of pain intensity and wound healing is done before the intervention, 24 hours after the intervention and then on the fifth and tenth days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahrokh Dolatian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Gynecology Department, In front of Shaheed Rajaee Heart Hospital, The intersection of Niayesh, Vali asr street, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717443</zip>
        <telephone>+98 21 8865 5366</telephone>
        <email>mhdolatian@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mahrokh Dolatian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing &amp; Midwifery, In front of Shahid Rajai Hospital, Niayesh Expressway, Valiasr St, District3, Tehran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717443</zip>
        <telephone>+98 21 8865 5366</telephone>
        <email>mhdolatian@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Married women aged 18 to 35 years primiparous
Being Iranian
Gestational age between 37 to 42 weeks
No smoking, alcohol and drugs
Being literate in reading and writing
Having a single fetus with cephalic presentation
Fetal weight between 2500 and 4000 gr
Body Mass Index (BMI) between 18.5 and 25
Vaginal delivery with mediolateral episiotomy
The normality of the first, second and third stages of labor</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Amniotic sac rupture more than 24 hours
Allergy to Malva sylvestris L ointment
Having fever, puerperal infection and hematoma
Infant hospitalization at Neonatal Intensive Care Unit
Having postpartum hemorrhoids or fissures
Having sex in the first ten days after delivery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O70</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Perineal laceration during delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: Uses 3% Malva sylvestris L ointment for 10 days (daily) at a rate of two centimeters, on episiotomy wound. This ointment is produced at the Faculty of Pharmacy of Shahid Beheshti University of Medical Sciences. Initial assessment of pain intensity and wound healing is done before the intervention, 24 hours after the intervention and then on the fifth and tenth days.</i_keyword>
      <i_keyword>Control group: Control group: Use placebo ointment (quite similar to Malva sylvestris L ointment) for 2 days (daily) at 2 cm, on episiotomy ulcer. This ointment is produced at the Faculty of Pharmacy of Shahid Beheshti University of Medical Sciences. Initial assessment of pain intensity and wound healing is done before the intervention, 24 hours after the intervention and then on the fifth and tenth days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Episiotomy wound healing. Timepoint: Before the intervention, the first 24 hours, 5 and 10 days after treatment. Method of measurement: REEDA scale assess 5 items such as Redness, Edema, Ecchymoses, Discharge from the wound and Approximation of the perineal tissues.</prim_outcome>
      <prim_outcome>Episiotomy wound pain intensity. Timepoint: Before the intervention, the first 24 hours, 5 and 10 days after treatment. Method of measurement: The visual pain scale (VAS) is a tool for measuring the intensity of pain, which is a 10 cm ruler with eleven numbers.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-31</approval_date>
        <contact_name>Ethics Committee of Pharmacy, Nursing and Midwifery Faculties of Shahid Beheshti University of Medic</contact_name>
        <contact_address>Block A, 13th floor, Central Headquarters of the Ministry of Health, Treatment and Medical Education, Simai Iran Street, between South Flamak and Zarafshan, Quds Town (West), Tehran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
